法因：癌症的一种新型分子靶标。
Fyn: a novel molecular target in cancer.
机构信息
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.
出版信息
Cancer. 2010 Apr 1;116(7):1629-37. doi: 10.1002/cncr.24879.
Abstract
Fyn is 59-kDa member of the Src family of kinases that is historically associated with T-cell and neuronal signaling in development and normal cellular physiology. Whereas Src has been heavily studied in cancer, less attention has been traditionally awarded to the other Src kinases such as Fyn. Our group has shown that Fyn is particularly upregulated in prostate cancer in contrast to the alternative members of the Src family. This suggests that it may mediate several important processes attributed to Src kinases in prostate cancer and other malignancies. These functions include not only cellular growth and proliferation but also morphogenesis and cellular motility. Together, these suggest a role for Fyn in both progression and metastasis. As several agents in clinical development affect Fyn activation, understanding the role that Fyn plays in cancer is of great importance in oncology. Cancer 2010. (c) 2010 American Cancer Society.
摘要
Fyn 是 Src 家族激酶的 59kDa 成员，在发育和正常细胞生理中与 T 细胞和神经元信号转导历史相关。虽然 Src 在癌症中得到了广泛研究，但传统上对其他 Src 激酶（如 Fyn）的关注较少。我们的研究小组表明，与 Src 家族的其他成员相比，Fyn 在前列腺癌中特别上调。这表明它可能介导归因于前列腺癌和其他恶性肿瘤中 Src 激酶的几个重要过程。这些功能不仅包括细胞生长和增殖，还包括形态发生和细胞迁移。总之，这表明 Fyn 在进展和转移中都发挥作用。由于几种处于临床开发阶段的药物会影响 Fyn 的激活，因此了解 Fyn 在癌症中的作用对于肿瘤学具有重要意义。癌症 2010.（c）2010 美国癌症协会。
相似文献
1
Fyn: a novel molecular target in cancer.法因：癌症的一种新型分子靶标。
Cancer. 2010 Apr 1;116(7):1629-37. doi: 10.1002/cncr.24879.
2
Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.Fyn 蛋白缺失是Src 家族激酶抑制剂诱导人胸膜间皮瘤细胞凋亡的必要条件。
Carcinogenesis. 2012 May;33(5):969-75. doi: 10.1093/carcin/bgs109. Epub 2012 Feb 21.
3
Distinct roles for N-Cadherin linked c-Src and fyn kinases in lens development.N-钙黏附蛋白连接的 c-Src 和 fyn 激酶在晶状体发育中的不同作用。
Dev Dyn. 2013 May;242(5):469-84. doi: 10.1002/dvdy.23935. Epub 2013 Mar 12.
4
FYN: emerging biological roles and potential therapeutic targets in cancer.FYN：癌症中新兴的生物学作用和潜在治疗靶点。
J Transl Med. 2023 Feb 5;21(1):84. doi: 10.1186/s12967-023-03930-0.
5
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.Fyn 位于 HGF/MET 信号轴的下游，影响 PC3 细胞的形态和趋向性。
Clin Cancer Res. 2011 May 15;17(10):3112-22. doi: 10.1158/1078-0432.CCR-10-1264. Epub 2011 Mar 1.
6
Src family kinases are required for integrin but not PDGFR signal transduction.Src家族激酶是整合素信号转导所必需的，但不是血小板衍生生长因子受体（PDGFR）信号转导所必需的。
EMBO J. 1999 May 4;18(9):2459-71. doi: 10.1093/emboj/18.9.2459.
7
SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.SRC家族激酶FYN促进晚期前列腺癌的神经内分泌表型和内脏转移。
Oncotarget. 2015 Dec 29;6(42):44072-83. doi: 10.18632/oncotarget.6398.
8
The Src family kinases: distinct functions of c-Src, Yes, and Fyn in the liver.Src家族激酶：c-Src、Yes和Fyn在肝脏中的不同功能。
Biomol Concepts. 2013 Apr;4(2):129-42. doi: 10.1515/bmc-2012-0047.
9
Vascular smooth muscle cell motility is mediated by a physical and functional interaction of Ca2+/calmodulin-dependent protein kinase IIδ2 and Fyn.血管平滑肌细胞的运动是由 Ca2+/钙调蛋白依赖性蛋白激酶 IIδ2 和 Fyn 的物理和功能相互作用介导的。
J Biol Chem. 2013 Oct 11;288(41):29703-12. doi: 10.1074/jbc.M113.477257. Epub 2013 Sep 3.
10
The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion.SRC家族激酶的抑制作用可抑制胰腺癌细胞的增殖、迁移和侵袭。
Pancreas. 2014 Jul;43(5):768-76. doi: 10.1097/MPA.0000000000000103.
引用本文的文献
1
The underlying molecular mechanisms of Fyn in neonatal hypoxic-ischaemic encephalopathy.Fyn在新生儿缺氧缺血性脑病中的潜在分子机制。
Front Cell Neurosci. 2024 Nov 27;18:1476856. doi: 10.3389/fncel.2024.1476856. eCollection 2024.
2
Cellular and molecular roles of reactive oxygen species in wound healing.活性氧在伤口愈合中的细胞和分子作用。
Commun Biol. 2024 Nov 19;7(1):1534. doi: 10.1038/s42003-024-07219-w.
3
Role of Fyn expression in predicting the sensitivity to platinum‑based chemotherapy in patients with ovarian serous carcinoma.Fyn表达在预测卵巢浆液性癌患者对铂类化疗敏感性中的作用。
Oncol Lett. 2024 Sep 2;28(5):525. doi: 10.3892/ol.2024.14658. eCollection 2024 Nov.
4
Identification of hub genes and therapeutic siRNAs to develop novel adjunctive therapy for Duchenne muscular dystrophy.鉴定 Duchenne 肌营养不良症的枢纽基因和治疗性 siRNA，开发新的辅助治疗方法。
BMC Musculoskelet Disord. 2024 May 18;25(1):386. doi: 10.1186/s12891-024-07206-6.
5
A novel CD8+ T cell-related gene signature as a prognostic biomarker in hepatocellular carcinoma.一种新型的 CD8+ T 细胞相关基因特征作为肝细胞癌的预后生物标志物。
Medicine (Baltimore). 2024 Mar 15;103(11):e37496. doi: 10.1097/MD.0000000000037496.
6
Dihydromyrcenol Modulates Involucrin Expression through the Akt Signaling Pathway.二氢大马酮通过 Akt 信号通路调节 Involucrin 的表达。
Int J Mol Sci. 2024 Feb 13;25(4):2246. doi: 10.3390/ijms25042246.
7
Fyn-mediated phosphorylation of Menin disrupts telomere maintenance in stem cells.Fyn介导的Menin磷酸化破坏干细胞中的端粒维持。
bioRxiv. 2024 Mar 19:2023.10.04.560876. doi: 10.1101/2023.10.04.560876.
8
An In Vitro Evaluation and Network Pharmacology Analysis of Prospective Anti-Prostate Cancer Activity from .来自……的潜在抗前列腺癌活性的体外评估及网络药理学分析
Plants (Basel). 2023 Aug 21;12(16):3006. doi: 10.3390/plants12163006.
9
Perhexiline: Old Drug, New Tricks? A Summary of Its Anti-Cancer Effects.佩尔地平：老药新用？其抗癌作用概述。
Molecules. 2023 Apr 21;28(8):3624. doi: 10.3390/molecules28083624.
10
Advances in the expression and function of Fyn in different human tumors.Fyn 在不同人类肿瘤中的表达和功能的研究进展。
Clin Transl Oncol. 2023 Oct;25(10):2852-2860. doi: 10.1007/s12094-023-03167-9. Epub 2023 Apr 24.
本文引用的文献
1
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.Src激酶抑制剂AZD0530用于晚期去势抵抗性前列腺癌患者的II期试验：一项加利福尼亚癌症联盟研究。
Anticancer Drugs. 2009 Mar;20(3):179-84. doi: 10.1097/CAD.0b013e328325a867.
2
FYN is overexpressed in human prostate cancer.FYN在人类前列腺癌中过表达。
BJU Int. 2009 Jan;103(2):171-7. doi: 10.1111/j.1464-410X.2008.08009.x. Epub 2008 Oct 16.
3
Activation of c-Src and Fyn kinases by protein-tyrosine phosphatase RPTPalpha is substrate-specific and compatible with lipid raft localization.蛋白酪氨酸磷酸酶RPTPα对c-Src和Fyn激酶的激活具有底物特异性，且与脂筏定位兼容。
J Biol Chem. 2008 Dec 19;283(51):35815-24. doi: 10.1074/jbc.M807964200. Epub 2008 Oct 23.
4
Early adhesion induces interaction of FAK and Fyn in lipid domains and activates raft-dependent Akt signaling in SW480 colon cancer cells.早期黏附诱导黏着斑激酶（FAK）和Fyn在脂筏结构域中相互作用，并激活SW480结肠癌细胞中依赖脂筏的Akt信号传导。
Biochim Biophys Acta. 2008 Dec;1783(12):2323-31. doi: 10.1016/j.bbamcr.2008.08.008. Epub 2008 Sep 5.
5
NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin.神经细胞黏附分子（NCAM）诱导的粘着斑组装：E-钙黏蛋白缺失后的功能转换
EMBO J. 2008 Oct 8;27(19):2603-15. doi: 10.1038/emboj.2008.178. Epub 2008 Sep 4.
6
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.AZD0530揭示的Src家族激酶在前列腺癌中的致癌潜力及通路
Oncogene. 2008 Oct 23;27(49):6365-75. doi: 10.1038/onc.2008.250. Epub 2008 Aug 4.
7
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.在原位裸鼠模型中，靶向SRC家族激酶可抑制前列腺癌的生长和淋巴结转移。
Cancer Res. 2008 May 1;68(9):3323-33. doi: 10.1158/0008-5472.CAN-07-2997.
8
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.PTEN的蛋白磷酸酶活性调节SRC家族激酶并控制胶质瘤迁移。
Cancer Res. 2008 Mar 15;68(6):1862-71. doi: 10.1158/0008-5472.CAN-07-1182.
9
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.在新建立的具有BCR-ABL基因扩增的K562变体中，使用Src抑制剂CGP76030、Abl抑制剂尼罗替尼和Abl/Lyn抑制剂INNO-406克服伊马替尼耐药性。
Int J Cancer. 2008 Jun 1;122(11):2621-7. doi: 10.1002/ijc.23435.
10
Nonreceptor tyrosine kinases in prostate cancer.前列腺癌中的非受体酪氨酸激酶
Neoplasia. 2007 Feb;9(2):90-100. doi: 10.1593/neo.06694.
Zotero 插件